Endocrine therapy mediated hot flushes in breast cancer: can exercise help? by France, MVK
 
 
 
 
 
Endocrine therapy mediated hot flushes in breast cancer: 
can exercise help? 
 
 
 
 
 
 
 
 
 
 
Madeleine France 
 
 
 
A thesis submitted in partial fulfilment of the 
requirements of Liverpool John Moores University 
for the degree of Master of Philosophy 
 
 
 
 
Study 2 was carried out in collaboration with the Royal Liverpool 
 and Broadgreen University Hospitals 
 
September 2018 
 
 
 
 
Abstract 
Introduction: Hot flushes are a sudden, intense sensation of heat causing skin reddening, 
flushing and profuse sweating. Hot flushes are a side effect of endocrine therapy for breast 
cancer treatment; and are possibly more frequent and severe than post-menopausal hot 
flushes. Many breast cancer patients do not adhere to the endocrine therapy guidelines 
due to the frequency and severity of hot flushes, which significantly increases the risk of 
cancer recurrence. There are currently few treatments able to reduce the frequency and 
severity of hot flushes in breast cancer. Exercise training has shown promise in alleviating 
menopausal hot flushes. Therefore, the overall aim of this thesis was to examine subjective 
and physiological frequency and severity of endocrine mediated hot flushes in breast 
cancer patients; and determine the effectiveness of an exercise training intervention in 
ameliorating endocrine mediated hot flushes.   
Methods: Eight breast cancer patients undergoing endocrine therapy (age 53 ± 8, BMI 29 
± 6) were recruited and 16 postmenopausal women experiencing hot flushes (age 53 ± 4, 
BMI 29 ± 5) from a previously reported study were included. A 7-day subjective hot flush 
frequency and severity questionnaire was used to examine subjective frequency and 
severity. To measure physiological frequency and severity sweat rate, skin and cerebral 
blood flow were measured in the laboratory. To do this women wore a tube-lined suit, 
which was perfused with 34°C water followed by a passive heat stress where water 
temperature increased to 48°C. A hot flush was objectively defined as a transient and 
pronounced increase in sternal sweat rate (>0.002 mg cm-2 min-1). Sweating and cutaneous 
vasodilatory temperature thresholds and sensitivities were identified during the passive 
heating. Cardiorespiratory fitness and vascular health were also measured. Breast cancer 
patients (n=5) then completed a progressive 16-week moderate-intensity exercise training 
intervention (30-60 minutes, 3-5x per week). After which, measurements were repeated. 
Data were analysed using t-tests and/or general linear modelling, and presented as mean 
(95% CI). 
Results: Despite similar subjective hot flush frequency (49, 58; 95%CI = -45, 26; P = 0.56) 
and severity (81, 125; 95%CI = -102, 13 AU; P = 0.12) in breast cancer patients and 
postmenopausal women, respectively breast cancer patients demonstrated attenuated 
sweating, skin and cerebral blood flow responses during a hot flush (P > 0.05). 16 weeks of 
 
 
exercise training did mediate reductions in subjective hot flush frequency by 37 hot flushes 
per week (52, 12; 95%CI = -21, 102, P = 0.14) and severity by 68 AU (78, 27; 95%CI = -39, 
166 AU; P = 0.16) but this did not reach statistical significance. Exercise training did not 
attenuate physiological responses to a hot flush as no differences in sweating, skin and 
cerebral blood flow responses occurred (P > 0.05). 
Conclusion: These data indicate that endocrine mediated hot flushes in breast cancer are 
not more severe than those experienced by post-menopausal women. Exercise training has 
shown promise as a potential non-pharmacological treatment for endocrine mediated hot 
flushes in breast cancer but requires further study. 
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1.1 Background 
A hot flush is defined as a sudden, intense sensation of heat causing skin reddening, 
flushing and profuse sweating (Low et al, 2008). Post-menopausal women without breast 
cancer have displayed elevations in skin blood flow (80%), sweating (5-fold) and reductions 
in cerebral blood flow during a hot flush (Sloan et al, 2001; Low et al, 2008; Lucas et al, 
2013). 
A type of endocrine therapy that suppresses oestrogen is prescribed after active breast 
cancer treatment. This prescription, however, causes hot flushes in ~70% of breast cancer 
patients (Antoine et al, 2008). Hot flushes are extremely debilitating and cause anxiety, 
depression, sleep disturbances and chronic fatigue (Gupta et al, 2006). Importantly, hot 
flushes may be more frequent and severe in breast cancer patients relative to naturally 
menopausal women (Carpenter et al, 2002) and are the main reason up to 90% of patients 
stop endocrine treatment early or reduce their dosage (Kligman and Younus, 2010). This 
has a significant impact on breast cancer prognosis (Murphy et al, 2012; Makubate et al, 
2013). 
The physiological changes that occur during a hot flush have not been thoroughly 
investigated in breast cancer patients. In one study, Carpenter et al (2004) reported that 
breast cancer patients subjectively under report hot flush occurrence in comparison to an 
objective measure of skin conductance. This could possibly be due to breast cancer patients 
being more or less ‘attuned’ to physical sensations. A subsequent study reported that 
subjective hot flush frequency and severity was greater in breast cancer patients by 4 hot 
flushes and 4 arbitrary units (AU) per 48 hours compared to postmenopausal females 
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(Carpenter et al, 2002). Substantiation of the severity between endocrine mediated and 
post-menopausal hot flushes and an objective physiological investigation is warranted.  
Pharmacological treatment of hot flushes in breast cancer is limited as hormone 
replacement therapy (HRT) is contraindicated. Given the prevalence of hot flushes and 
their impact on adherence to endocrine therapy, alternative treatments are essential. One 
study has investigated the combined and individual effects of cognitive behavioural therapy 
(CBT) and exercise training on subjective frequency and severity of endocrine mediated hot 
flushes in breast cancer and found that the interventions combined were more beneficial 
in comparison to CBT or exercise training alone (Duijts et al, 2012). Along similar lines, the 
effect of exercise training on post-menopausal hot flushes has shown promising results as 
a non-pharmacological alternative treatment (Karacan, 2010; Luoto et al, 2012; Reed et al, 
2014; Bailey et al, 2016a; Bailey et al, 2016b). In one study, Bailey et al (2016b) employed 
a 16-week moderate intensity aerobic exercise training intervention in postmenopausal 
women experiencing hot flushes. Subjective frequency and severity of hot flushes (Sloan et 
al, 2001) and physiological measures of hot flushes in a laboratory setting using sweating, 
skin and cerebral blood flow, were reduced following exercise training. The exercise 
training intervention was also successful in increasing cardiorespiratory fitness and 
improving thermoregulatory and vascular control, which may provide some explanation 
into how exercise can improve severity of hot flushes. Taken together, exercise training 
may be a useful intervention that requires further investigation into the objective and 
physiological changes that might occur in breast cancer patients.  
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1.2 Summary 
The overall aim of this thesis was to examine subjective and objective endocrine mediated 
hot flushes in breast cancer patients and to determine the effect of exercise training. This 
aim will be realised via two experimental studies: 
(i) To compare the subjective as well as objective physiological frequency and 
severity of hot flushes between post-menopausal women and breast cancer 
patients undergoing endocrine therapy  
(ii) To investigate the effect of 16 weeks of moderate intensity aerobic exercise 
training on the frequency and severity of hot flushes as well as cardiovascular 
health in breast cancer patients taking endocrine therapy  
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2 Literature Review 
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2.1  Introduction 
This literature review will provide an overview of available research studies that have 
investigated hot flushes in breast cancer patients undergoing endocrine therapy and 
postmenopausal women. Secondly, this review will highlight the potential of exercise as a 
non-pharmacological alternative to alleviate hot flushes.  
2.1.1 Breast cancer 
Breast cancer is the most common form of cancer in the UK and incidence in the UK has 
increased by ~4% over the last decade (Cancer Research UK, 2018). More than 80% of 
breast cancer occurs in women over the age of 50 (Breast Cancer Care, 2018). Due to 
increasing life expectancy, incidence rates of breast cancer are expected to further rise by 
2% by 2035 (Cancer Research UK, 2018). Breast cancer survival rates in the UK have 
improved significantly over the past 50 years (Cancer Research UK, 2018), therefore, a large 
number of women are living with the after effects of the disease and its treatment. 
Treatment for breast cancer is dependent on various factors including: (1) the type of 
cancer, (2) stage of the disease, and (3) whether the cancer has metastasized. Treatment 
can consist of chemotherapy, radiotherapy and surgery or any combination of these. Breast 
cancers can be hormone-receptor positive, for example oestrogen receptor positive (ER+) 
or progesterone receptor positive (PR+). In ER+ and PR+ breast cancers, cells contain 
oestrogen or progesterone receptors respectively that enable tumours to grow. There are 
also hormone-receptor negative breast cancers, for example human epidermal growth 
factor receptor 2 positive (HER2+). These proteins are receptors on breast cells that grow 
and divide exponentially. There are also triple-negative breast cancers, which possess no 
oestrogen or progesterone receptors and do not overexpress HER2. HER2+ only breast 
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cancer and triple-negative breast cancer are uncommon consisting of only 10-20% of breast 
cancers.  
Approximately 80% of breast cancers are ER+ (Kohler et al, 2015) and the focus of this thesis 
is on ER+ breast cancers. Individuals with ER+ breast cancers are much more likely to 
respond to endocrine therapy that supress oestrogen. Endocrine therapy is usually 
prescribed to women recovering from ER+ breast cancer after completion of ‘active’ cancer 
treatment (e.g. chemotherapy, radiotherapy or surgery) as it can reduce the risk of breast 
cancer recurrence but in some instances it can be used to reduce the size of the cancerous 
tumour before surgery to remove it or can treat breast cancer that has returned or 
metastasized. Different types of endocrine therapy possess various strategies of action and 
are prescribed to women dependent on menopausal status. Strategies include providing 
ovarian ablation (blocking ovarian function), blocking oestrogen production or blocking 
oestrogens effects. Aromatase inhibitors (AIs) prevent the conversion of androgens into 
oestrogens in muscle and peripheral adipose tissue (Mom et al, 2006). AIs such as 
anastrozole, letrozole and exemestane, are prescribed solely to postmenopausal women 
as the ovaries in premenopausal women produce too large a quantity of aromatase for the 
inhibitors to block effectively (National Cancer Institute, 2017). Selective oestrogen 
receptor modulators (SERMs), such as tamoxifen, can be prescribed to pre and 
postmenopausal women. SERMs block the effects of oestrogen through binding to 
oestrogen receptors. AIs and SERMS are the most commonly prescribed endocrine therapy. 
In recovery from breast cancer (i.e. following active treatment), endocrine therapy is 
recommended for a minimum of 5 years in ER+ breast cancer patients. Meta-analyses have 
shown that in ER+ breast cancers, full compliance with 5 years of tamoxifen can reduce 
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breast cancer mortality rate during the first 15-years after the start of treatment by at least 
a third (Early Breast Cancer Trialists' Collaborative, 2011). Similarly, AIs have been shown 
to reduce breast cancer mortality rate by around 40% throughout the first decade of 
treatment (Early Breast Cancer Trialists' Collaborative, 2015).  
Importantly, 31-73% of breast cancer patients prescribed tamoxifen or AIs following active 
treatment discontinued treatment before the end of the recommended five-years and 41-
72% did not adhere to the prescribed frequency of use (e.g. daily) (Murphy et al, 2012). The 
poor compliance to AIs or tamoxifen is predominately due to the side effect, hot flushes 
(Kligman and Younus, 2010). Hot flushes occur as a result of the loss of oestrogen action as 
a consequence of the endocrine treatment. In one study breast cancer patients subjectively 
reported significantly more frequent, severe and “bothersome” hot flushes compared to 
naturally postmenopausal women (Carpenter et al, 2002). In that study, Carpenter and 
colleagues recruited 69 breast cancer patients, 50% of which were taking tamoxifen, and 
63 age-matched healthy pre-, peri- and postmenopausal females (Carpenter et al, 2002). A 
subjective hot flush questionnaire (Kronenberg, 1994) and a 48-hour hot flush diary were 
utilised. They found that hot flush frequency and severity were 4 hot flushes and 4 arbitrary 
units (AU) greater, respectively, per 48 hours in breast cancer patients compared to 
postmenopausal females. Moreover, hot flushes were 3 minutes greater in duration 
measured using subjective diaries in breast cancer patients undergoing endocrine therapy. 
Tamoxifen increases the prevalence of hot flushes in comparison to placebo (Fisher et al, 
1998; Fallowfield et al, 2001). Aromatase inhibitors are also associated with a similar 
prevalence of hot flushes as tamoxifen (Fallowfield and Cella, 2002). Intriguingly, despite 
potential greater severity, breast cancer patients have been shown to subjectively under 
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report hot flushes, which have met the objective criteria required to be considered a hot 
flush (Carpenter, Monahan and Azzouz, 2004). An increase in skin conductance of at least 
2 µmho within a 30 second period was required to define an objective hot flush (Carpenter, 
Monahan and Azzouz, 2004). Carpenter et al (1999) recruited 19 postmenopausal breast 
cancer patients, three of which were taking tamoxifen, and five healthy premenopausal 
women.  24-hour ambulatory sternal skin conductance monitoring was employed in this 
study as well as a subjective hot flush diary; skin conductance monitoring during waking 
hours was associated with a 30% false-negative rate. This could imply that hot flush 
frequency data reported in studies utilising skin conductance monitoring may be 
underestimated (Carpenter et al, 2002). Nevertheless, sternal skin conductance data 
should also be interpreted with caution given that sternal skin conductance monitoring 
could not differentiate between sweating from a hot flush and sweating due to performing 
exercise/physical activity (Carpenter, Monahan and Azzouz, 2004). Research studies with 
more reliable measurement of objective frequency and severity of hot flushes, e.g. 
physiological changes, other than skin conductance, are required.   
2.1.2 Postmenopausal hot flushes  
The most common side effect of the menopause are hot flushes (Thurston, 2018). A 
menopausal hot flush is a sudden, intense sensation of increasing heat causing skin 
reddening, flushing and profuse sweating (Low et al, 2008). Research studies have shown 
during a menopausal hot flush, elevations in skin blood flow (80%), sweating (500%) a 
reduction (5%) in cerebral blood flow occur (Sloan et al, 2001; Low et al, 2008; Lucas et al, 
2013). 
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2.2 The physiology of a hot flush 
Previous studies measuring physiological hot flushes using measures such as Laser Doppler 
flowmetry and capacitance hygrometry have found that increases in skin temperature and 
skin blood flow occur prior to an increase in sweating (Figure 2.1) (Low et al, 2008; Hubing 
et al, 2010; Low et al, 2011; Lucas et al, 2013; Bailey et al, 2016a). Blood from the central 
regions is redistributed to the peripheral regions, which can lead to large increases in 
systemic vascular conductance and reductions in blood pressure (Crandall et al, 2008; Low 
et al, 2008). Low et al. (2011) found that increases in skin blood flow and cutaneous vascular 
conductance (CVC) during a hot flush are inhibited by botulinum toxin A (BTX), which blocks 
the release of neurotransmitters from sympathetic cholinergic nerves. In the absence of an 
increase in core body temperature, increases in efferent sympathetic nerve activity to the 
skin were observed prior to and during a hot flush (Low et al, 2011), likely influencing 
changes in sweating and skin blood flow. Additionally, increases in activity in the brainstem 
using function magnetic resonance imaging (fMRI) were observed prior to the onset of a 
hot flush, followed by significant increases in insula and prefrontal cortex activity 
(Diwadkar, Murphy and Freedman, 2013). This suggests that increases in skin blood flow 
and sweating may be neurally mediated rather than ‘locally’ or non-neurally mediated 
(Freedman, Woodward and Mayes, 1994).  
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Figure 2.1 Example of thermoregulatory response during a hot flush A) pink trace is ECG B) 
orange trace is core temperature C) green trace and red trace are chest and forearm skin 
blood flow, respectively D) purple and blue trace are chest and forearm sweat rate, 
respectively. 
 
A reduction in central blood volume during a hot flush may be accompanied by a reduction 
in end-tidal carbon dioxide, which could contribute to a drop in cerebral blood flow as seen 
during passive heat stress (Brothers et al, 2009; Nelson et al, 2011). According to Lucas et 
al. (2013), 66% of hot flushes in 11 healthy postmenopausal women were accompanied by 
a 5% reduction in cerebral blood flow. The transient decrease in middle cerebral artery 
velocity (MCAv) could be responsible for the possible feelings of dizziness or nausea 
associated with a hot flush. Collectively, there is a large suite of studies describing the 
physiological changes during a menopausal hot flush. It is assumed that such changes also 
occur in a hot flush mediated by endocrine treatment in recovery from breast cancer. This, 
however, warrants further investigation as endocrine therapy may mechanistically mediate 
hot flushes differently in breast cancer patients compared to naturally occurring 
postmenopausal hot flushes.  
A) 
B) 
C) 
D) 
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2.2.1 Mechanisms contributing to menopausal hot flushes 
The physiological mechanisms associated with menopausal hot flushes are unclear. One 
explanation for the onset of a hot flush is an increase in core body temperature (Freedman 
and Woodward, 1996; Freedman, 2014). An increase in core body temperature of 0.03-
0.05°C in the 30 minutes prior to a hot flush was apparent in 65% of hot flushes in 8 
symptomatic postmenopausal women (Freedman and Krell, 1999). Later findings 
suggested that core body temperature fluctuates by 0.035°C during a 24-hr period in both 
symptomatic and non-symptomatic post-menopausal women and importantly, these 
fluctuations in core body temperature do not trigger a hot flush (Freedman, 2002). As a 
consequence, other mechanisms have been proposed. Changes in neurotransmitters in the 
brain have been suggested, for example hypothalamic neurokinin B (NKB) that is increased 
during the menopause. Intravenous infusion of hypothalamic NKB resulted in 8 out of 10 
women experiencing a hot flush, measured using sternal skin conductance (Jayasena et al, 
2015). Furthermore, alterations in the sympathetic nervous system may be associated with 
hot flushes. Low et al. (2011) observed increases in sympathetic nerve activity to the skin 
during a hot flush and proposed that these increases are potentially due to an elevation in 
a singular or multiple neural component such as cutaneous vasoconstrictor, sudomotor 
and/or vasodilator neural activities.  
Vascular (dys)function may be implicated in the severity of hot flushes (Mendelsohn and 
Karas, 1999; Bechlioulis et al, 2010; Bechlioulis et al, 2012; Sassarini et al, 2012; Sassarini 
et al, 2014). Postmenopausal women exhibit reduced flow mediated dilation (FMD) (a 
marker of large artery nitric oxide function) compared to males and premenopausal 
females (Thurston et al, 2008; Moreau et al, 2012) and possess higher levels of vascular 
inflammatory markers indicative of vascular dysfunction compared to premenopausal 
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females (Nyberg et al, 2014). Moreover, Bechlioulis et al. (2010) found women with more 
severe hot flushes had significantly lower FMD compared with menopausal women with 
no/mild hot flushes (Bechlioulis et al, 2010). It has been suggested that postmenopausal 
women with severe hot flushes may possess negatively altered vascular regulatory 
mechanisms (Najjar, Scuteri and Lakatta, 2005) or elevated sympathetic tone (Ganong, 
2001). 
There is emerging research evidence that post-menopausal women who demonstrate 
vasomotor symptoms (e.g. hot flushes) have a higher prevalence of cardiovascular disease 
(CVD) risk factors and novel markers of vascular function (FMD) using Doppler ultrasound 
(Thurston et al, 2011; Gray et al, 2018). Vasomotor symptoms (increased severity and 
duration of hot flushes) were associated with an 18% increased type 2 diabetes mellitus 
(T2DM) risk (Gray et al, 2018). Taken together the presence of hot flushes may be an 
important and independent marker of health.  
2.2.2 Treatment for the endocrine meditated hot flushes 
The clinical need for therapies to alleviate hot flush symptoms in breast cancer patients has 
been highlighted by the National Cancer Research Institute (NCRI) Breast Cancer Symptom 
Management group (Morgan and Fenlon, 2013) and the National Institute for Health and 
Care Excellence (NICE) guidelines for menopause (NICE, 2015). Yet, little is known about by 
endocrine mediated hot flushes.  
Cognitive behavioural therapy is one non-pharmacological treatment that has been 
examined. Cognitive behavioural therapy is a talking therapy, which encourages individuals 
to change their behaviour and mind-set to help relieve problems. Various methodologies 
for program implementation has been employed, including internet-based (Atema et al, 
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2017) and group sessions (Duijts et al, 2012; Mann et al, 2012). Each program strategy of 
CBT found significant reductions of 1-3 AU in hot flush problem ratings. Duijts et al. (2012) 
investigated the effect of CBT and physical exercise on overall menopausal symptoms. 
Duijts and colleagues found that both physical exercise and CBT interventions combined 
significantly decreased short- and long-term overall endocrine symptoms, specifically hot 
flushes, compared with the control group. The study demonstrated a significant decrease 
of 1.3 AU in hot flushes and night sweats problem ratings. These findings suggest that 
physical exercise may be beneficial for reducing menopausal symptoms in breast cancer 
patients. Physical exercise alone, however, demonstrated an insignificant decrease of 0.45 
AU. Nonetheless, this intervention did not include participant exercise supervision and may 
not have been of a sufficient exercise intensity. Given the knowledge of the importance of 
exercise intensity and supervision for optimal training intervention effects (see below) and 
the positive impact of exercise training in post-menopausal women, further research into 
the effect of exercise training on endocrine therapy hot flushes is warranted.  
2.2.3 The effect of exercise training on hot flushes in postmenopausal women 
Various studies exist that have directly measured the impact of exercise training on 
subjective hot flushes (Lindh-Astrand et al, 2004; Luoto et al, 2012; Moilanen et al, 2012; 
Reed et al, 2014; Daley et al, 2015; Bailey et al, 2016a; Bailey et al, 2016b). Exercise training 
has elicited a decrease in hot flush frequency in the range of 4 to 64% and severity in the 
range of 5 to 70% (Table 2.1). As an example, Bailey et al. (2016) compared the mean 
number of self-reported hot flushes per week between an exercise intervention and no-
intervention control. After adjusting for baseline hot flush frequency/severity, the mean 
frequency of hot flushes per week was 48 events (70%) lower following the exercise 
intervention (mean: 18 events/week) vs. following a same period of no-intervention 
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control (95%CI for mean difference: 39 to 56 events/week, P < 0.001). It is important to 
highlight that not all studies have reported a statistically significant reduction in hot flush 
frequency following a period of exercise training compared with control (Newton et al, 
2014; Sternfeld et al, 2014; Daley et al, 2015). Nevertheless, a number of these studies have 
employed a lower intensity exercise stimulus and duration as discussed previously or with 
appropriate guidance to cause an increase in cardiorespiratory fitness; or, in some studies, 
they did not even assess cardiorespiratory fitness. Overall, higher exercise intensity and 
longer duration of intervention as well as monitoring adherence generally mediated the 
largest improvements in hot flush frequency and severity (Table 2.1). For example, aerobic 
exercise training interventions performed at moderate-high intensity for a duration of ≥ 12 
weeks demonstrated significant improvements in hot flush frequency and severity (Lindh-
Astrand et al, 2004; Karacan, 2010; Luoto et al, 2012; Bailey et al, 2016a; Bailey et al, 
2016b). 
Taken together, all of the exercise training studies performed prior to 2015 (Table 2.1), 
were included in the recommendations for the National Institute for Health and Care 
Excellence and North American Menopause Society guidelines on menopausal treatment 
(Carpenter et al, 2015; Sarri, Davies and Lumsden, 2015). This included systematic reviews 
on exercise and menopausal symptoms which reported that the data on exercise training 
is inconclusive due to a lack of controlled studies (n = 5 included) (Daley, Stokes-Lampard 
and Macarthur, 2009; Daley, Stokes-Lampard and Macarthur, 2011). Nevertheless, one 
focus of these systematic reviews was a comparison of exercise training interventions to 
HRT. Whilst it is well established that hot flushes are alleviated by hormone replacement 
therapy (HRT), any lifestyle intervention will be different from HRT mechanistically as 
oestrogen will still be low. The systematic review data led to exercise not being 
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recommended for menopause management or included in these guideline documents. Yet, 
the research studies that have been published since, including the suite of studies from 
Copenhagen Women’s study (Agil et al, 2010; Moilanen et al, 2012; Nyberg et al, 2014; 
Bailey et al, 2016a; Bailey et al, 2016b; Egelund et al, 2017; Mandrup et al, 2017a; Mandrup 
et al, 2017b; Nyberg et al, 2017; Seidelin et al, 2017), suggest positive benefits of exercising 
in the menopausal transition. One study examined the impact of exercise training on 
objective physiological responses to menopausal hot flushes for the first time (Bailey et al, 
2016a). In the aforementioned study, participants completed a 16-week moderate 
intensity exercise training intervention, and physiological measurements of core body 
temperature, sweat rate, skin and cerebral blood flow were recorded. They found that 
exercise training reduced the sweating and skin blood flow response typically observed 
during a hot flush episode as well as an attenuated decrease in cerebral blood flow (Bailey 
et al, 2016a). The physiological changes were also related to reductions in the subjective 
description of sweating, skin reddening, and feeling faint/light headedness. This provided 
direct evidence that exercise training reduced the physiological and subjective severity of 
menopausal hot flushes through the improvement of thermoregulatory and systemic 
vascular responses during a hot flush. 
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Table 2.1 The exercise training-mediated changes in hot flush frequency and severity 
measured using subjective rating scales. 
 Author Exercis
e 
modalit
y 
Exerci
se 
freque
ncy 
Exercis
e 
duratio
n 
(weeks) 
Time 
since 
menopa
use 
(years) 
Scale Chan
ge in 
frequ
ency 
Chan
ge in 
sever
ity 
H
ig
h
 in
te
n
si
ty
 Sternfel
d et al., 
2014 
Aerobic 
exercise 
60 min 
3x/we
ek 
12 N/A Daily 
diaries 
33% 17% 
Karacan
., 2010 
Aerobic 
exercise 
55 
mins 
3x/we
ek 
24 N/A Menopau
se Rating 
Scale 
N/A 5%* 
M
o
d
er
at
e
 in
te
n
si
ty
 
Bailey et 
al., 
2016a,b 
Aerobic 
exercise 
60 min 
5x/we
ek 
16 1-4 Sloan 64%* 72%* 
Lindh-
Åstrand 
et al., 
2004 
Aerobic 
exercise 
60 min 
3x/we
ek 
36 N/A Kupperma
n’s Index 
50% 39% 
Daley et 
al., 2015 
Aerobic 
exercise 
30 min 
5x/we
ek 
24 N/A Hot flush 
rating 
scale 
22% N/A 
Luoto et 
al., 2012 
Aerobic 
exercise 
50 min 
3x/we
ek 
12 0.5-2 Women’s 
Health 
Questionn
aire 
4%* 17% 
Moilane
n et al., 
2012 
Aerobic 
exercise 
50 
mins 
4x/we
ek 
24 0.5-3 Women's 
Health 
Questionn
aire 
† † 
Lo
w
 in
te
n
si
ty
 
Newton 
et al., 
2014 
Yoga 4x/we
ek 
12 N/A Daily 
diaries 
35% 15% 
Reed et 
al., 2014 
Aerobic 
exercise 
60 
mins 
3x/we
ek 
12 < 5 Menopau
sal Quality 
of Life 
N/A 22%* 
Reed et 
al., 2014 
Yoga 1x/we
ek + 
20mins 
practic
e daily 
12 < 5 Menopau
sal Quality 
of Life 
N/A 23%* 
N/A: not recorded; †unable to determine values; *statistically significant change compared to 
baseline 
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2.3  How does exercise mediate improvements in hot flushes? 
Based on the physiology of a hot flush and the suggested mechanisms mediating the 
frequency and severity of menopausal hot flushes (described above), the cardiovascular 
and thermoregulatory control systems are logical physiological targets in the causal 
pathway for an exercise exposure for alleviating hot flush outcomes. Both of these 
physiological systems become dysfunctional during the menopause and are implicated in 
the causal pathway for menopausal hot flushes (Deecher and Dorries, 2007). Only one 
study to date, described above, has attempted to investigate the pathways of how exercise 
training could alleviate menopausal hot flushes (Bailey et al. 2016a, 2016b). After 16 weeks 
of exercise training that would have induced regular, episodic increases in shear stress, 
increases in FMD, and reductions in body temperature thresholds for sweating and 
cutaneous vasodilation were observed indicating improved endothelial function and 
thermoregulatory efficiency respectively. These improvements in endothelial function and 
thermoregulation coincided with reductions in physiological and subjective hot flush 
frequency and severity. This provides support that these physiological systems could be 
involved in the alleviation of hot flushes. Whilst, there may be other systems involved (e.g. 
sympathetic nervous system), exercise-mediated changes require further study in post-
menopausal and endocrine mediated hot flushes. 
2.4 Associated benefits of exercise on menopausal symptoms in postmenopausal 
women  
Recently, a small number of research studies have examined the impact of exercise training 
on menopausal symptoms (Lindh-Astrand et al, 2004; Agil et al, 2010; Karacan, 2010; Luoto 
et al, 2012; Mansikkamaki et al, 2012; Moilanen et al, 2012; Newton et al, 2014; Reed et al, 
2014; Sternfeld et al, 2014; Daley et al, 2015; Bailey et al, 2016a; Bailey et al, 2016b). 
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Predominantly, the studies have utilised menopause specific measurement tools including 
the Menopause Quality of Life (MQOL) questionnaire (Hilditch et al, 1996), Menopause 
Rating Scale (MRS) (Heinemann et al, 2004) or Greene Climacteric Scale (Greene, 1998), 
which provide subjective data as the primary outcome. Generally, all of the exercise 
training studies show benefit in improving quality of life and subjective menopausal 
symptoms in post-menopausal women (Lindh-Astrand et al, 2004; Agil et al, 2010; Karacan, 
2010; Luoto et al, 2012; Mansikkamaki et al, 2012; Moilanen et al, 2012; Newton et al, 
2014; Reed et al, 2014; Sternfeld et al, 2014; Daley et al, 2015; Bailey et al, 2016a; Bailey et 
al, 2016b). For example, some studies have shown that exercise training improves 
psychological symptoms such as depression, anxiety and insomnia (Agil et al, 2010; 
Mansikkamaki et al, 2012; Moilanen et al, 2012; Newton et al, 2014; Sternfeld et al, 2014; 
Daley et al, 2015) whilst others reported benefits in physical symptoms such as urogenital 
symptoms (Karacan, 2010).  Importantly, and in line with the exercise training benefits on 
fitness, the magnitude of the intensity and duration of exercise training likely mediates the 
extent of the benefits. Low intensity exercise, including yoga, have observed improvements 
in menopause related quality of life (Elavsky and McAuley, 2007; Reed et al, 2014), whereas 
other studies that employed higher intensity aerobic exercise training found improved 
somatic, psychological and urogenital symptoms (Karacan, 2010).  
2.5 Breast cancer and exercise 
2.5.1 Can exercise increase cardiorespiratory fitness in breast cancer patients? 
Whilst, cardiorespiratory fitness in breast cancer patients is impaired (Jones et al, 2007; 
Peel et al, 2014), the majority of exercise training studies show fitness can be improved 
(Nieman et al, 1995; Burnham and Wilcox, 2002; Kolden et al, 2002; Courneya et al, 2003; 
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Hutnick et al, 2005; Lane, Jespersen and McKenzie, 2005; Pinto et al, 2005; Cheema and 
Gaul, 2006; Herrero et al, 2006), with only one study showing non-significant increases 
(Turner, Hayes and Reul‐Hirche, 2004). Generally, exercise training protocols utilising 
aerobic exercise with longer intervention durations are able to show the largest 
improvements in cardiorespiratory fitness in breast cancer patients. Taken together, these 
studies suggest that exercise training can mediate positive health effects even with 
evidence of fatigue and lymphedema, common side effects of cancer treatment (Courneya 
et al, 2003; Pinto et al, 2005). 
2.5.2 Associated benefits of exercise on menopausal symptoms in breast cancer 
patients undergoing endocrine therapy 
Few studies have investigated the effect of exercise on menopausal symptoms in breast 
cancer patients. It is plausible to assume that increases in cardiorespiratory fitness in breast 
cancer patients, results in benefits in QOL and menopausal symptoms, likewise to 
postmenopausal women. Studies investigating the impact of exercise training on QOL 
outcomes have utilised subjective questionnaires such as World Health Organisation QOL 
Assessment Scale (World Health Organization, 1995) and Functional Assessment of Cancer 
Therapy-Breast (FACT-B) scales (Brady et al, 1997). Overall QOL has been shown to increase 
after exercise training consisting of aerobic exercise and/or resistance training (Courneya 
et al, 2003; Cheema and Gaul, 2006). Low intensity exercise, such as yoga, has improved 
menopausal symptoms such as joint pain, fatigue and negative mood (Carson et al, 2009). 
Yet, the generalisability of these findings is restricted by the small sample size and use of 
only subjective diaries (Sloan et al, 2001). Although only a small amount of evidence exists 
to date, data suggests that exercise training is an effective intervention to improve 
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menopausal symptoms, in breast cancer survivors, yet only one study to date has 
investigated hot flushes as an outcome (Duijts et al, 2012). 
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Table 2.2 Summary of cardiorespiratory fitness changes from exercise training studies 
performed in breast cancer patients.  
 Author Exercise 
modality 
Exercise 
frequency 
Exercise 
duration 
(weeks) 
Time since 
treatment 
(months) 
Change in 
fitness (ml. 
kg-1.min-1) 
H
ig
h
 in
te
n
si
ty
 
Courneya 
et al., 
2003 
Aerobic 
exercise 
15-35 mins 3x 
per week 
15 12 2.7* 
Herrero et 
al., 2005 
Mixed. 
Aerobic 
exercise 
and RT 
Aerobic 
exercise: 20-
30 mins 3x per 
week. RT: 3x 
per week 
24 24-60 2.2* 
Turner et 
al., 2004 
Mixed. 
Aerobic 
exercise 
and RT 
Aerobic 
exercise and 
RT 1x per 
week. 
8 Median of 
17 
2.0 
Nieman et 
al., 1994 
Mixed. 
Aerobic 
exercise 
and RT 
60 mins 3x per 
week  
8 <48 Increase in 
walk test 
distance* 
M
o
d
er
at
e
 in
te
n
si
ty
 
Thorsen et 
al., 2005 
Aerobic 
exercise 
30 minutes 
home-based 
exercise 2x 
per week 
14 1 6.4* 
Burnham 
& Wilcox., 
2002 
Aerobic 
exercise 
14-32 mins 3x 
per week 
10 2 6.1* 
Kolden et 
al., 2002 
Aerobic 
exercise 
One hour 
group classes 
3x per week 
16 N/A 4.6* 
Hutnick et 
al., 2005 
Mixed. 
Aerobic 
exercise 
and RT 
Aerobic 
exercise: 40-
90 mins 3x per 
week. RT: 3x 
per week. 
24 2 weeks 3.3* 
Cheema & 
Gaul., 
2006 
Mixed. 
Aerobic 
exercise 
and RT 
Aerobic 
exercise: 15-
30 mins 3x per 
week. RT: 2x 
per week 
8 >6 1.5* 
Pinto et 
al., 2005 
Aerobic 
exercise 
2-5x per week 12 <60 Decrease in 
walk test 
time* 
Abbreviations: RT, Resistance training; N/A, not recorded, *statistically significant change from 
baseline, P < 0.05 
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Summary 
This literature review aimed to highlight the similarities and differences between hot 
flushes experienced during the menopause compared to those mediated by endocrine 
therapy in breast cancer. The role of exercise training as a non-pharmacological tool to 
alleviate hot flushes associated with breast cancer is highlighted. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
29 
 
 
 
3 General Methods 
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3.1 General methods 
The measurements and protocols undertaken in this thesis are utilised in both studies. This 
general methods chapter describes participant information, techniques of subjective and 
physiological measurements, protocols and data reduction methods. Specific research 
designs, protocols and statistics for each study are outlined within the respective chapters.  
3.1.1 Participants  
Participants were informed of the experimental procedure and any associated risks verbally 
and in writing before providing written informed consent. All participants reported 
experiencing at least four hot flushes over a 24-hour period. Participants were recruited 
from one of two studies, both having conformed to the Declaration of Helsinki and gained 
ethical approval by the National Research ethics committee. 
3.2 Measurements 
3.2.1 Subjective hot flush frequency and severity:   
Participants completed a 7-day hot flush frequency and severity diary (Sloan et al, 2001). 
The use of subjective hot flush diaries is a validated method to acquire subjective data for 
hot flush symptoms and perceptions (Sloan et al, 2001) and has been utilised in a number 
of hot flush research studies (Luoto et al, 2012; Moilanen et al, 2012; Sternfeld et al, 2014; 
Bailey et al, 2016a; Bailey et al, 2016b). Participants recorded the number of hot flushes 
per day along with the severity of each hot flush on a scale of 1 to 4 (1 being mild, 2 
moderate, 3 severe, and 4 very severe). This data provided a weekly hot flush score. Daily 
hot flush severity was calculated using the sum of hot flushes recorded into each severity 
rating, that is [(3 x 1 (mild)) + (4 x 2 (moderate)) + (1 x 3 (severe)) + (0 x 4 (very severe)) = 
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daily severity score of 14]. A hot flush severity index was then calculated by the total sum 
of daily severity scores over the 7-day period.   
3.2.2 Cardiorespiratory fitness: 
A fitness test for peak oxygen uptake (VO2peak) was performed on a treadmill (H/P Cosmos, 
Germany) using a modified Bruce protocol. A facemask was worn which was connected to 
an online gas analysis system (Oxycon Pro, Jaegar, Germany). After a 2-minute warm-up at 
2.2 km/h on a flat gradient, the initial workload was set at 2.7 km/h at a 5° gradient. 
Thereafter, continuous increments in speed and gradient were performed each minute 
until volitional exhaustion. Heart rate was measured continuously using short-range 
telemetry (RS800, Polar, Finland) and ratings of perceived exertion (Borg, 1998) were 
collected throughout. VO2peak was calculated from expired gas fraction (Oxycon Pro, Jaegar, 
Hochberg, Germany) as the highest 15-second period of data in the final minute before 
volitional exhaustion.  
3.2.3 Vascular function:  
Brachial artery endothelium-dependent function was measured using the FMD technique. 
Measurements were performed in a supine position after 20 minutes of rest. A Duplex 
ultrasound image was recorded for 1-minute (T300; Terason, Burlington, MA) to obtain 
baseline diameter and velocity. After baseline, recording was paused and a rapid inflation 
pneumatic cuff (D.E. Hokanson, Bellevue, UK) positioned on the forearm, distal to the 
brachial artery and was inflated to ~220 mmHg for a period of 5 minutes to induce ischemia. 
Diameter and velocity recordings were resumed 30 seconds before cuff deflation and were 
recorded for an additional 3 minutes, in accordance with recent technical specifications 
(Thijssen et al, 2011).  
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Analysis of brachial artery diameter was performed using custom-designed edge-detection 
and wall-tracking software, which is largely independent of investigator bias. A detailed 
description of the analysis methodology can be found in recent papers (Black et al, 2008; 
Thijssen et al, 2011). Blood flow was calculated at 30 Hz from synchronized diameter and 
velocity data. Shear rate was calculated as four times mean blood velocity per vessel 
diameter. Allometric scaling was subsequently performed to consider baseline vessel 
diameter.  
3.2.4 Temperature and blood flow responses to thermal heating: 
Participants were fitted in a tube-lined jacket and trousers (Meg-Eng, Ottawa Canada), 
which covered the entire body except for the head, feet, and the right forearm. Participants 
rested for 15 minutes in a semi recumbent position whilst 34°C water was perfused through 
the suit. Ten minutes of thermoneutral rest ensued before a passive heat stress was 
induced with 48°C water perfused through the suit for 60 minutes or until a rise of 
approximately 1°C in core body temperature occurred. The following measurements were 
recorded throughout.  
Heart rate was obtained using a 3-lead ECG (PowerLab; ADInstruments, Oxford, UK), 
alongside continuous beat-by-beat arterial blood pressure (BP) via finger 
photoplethysmography (Finapress, Amsterdam, the Netherlands). Stroke volume (SV) and 
cardiac output (CO) were calculated using the BP waveform using the Modelflow method, 
incorporating age, height, sex, and weight as moderator variables (Beatscope 1.0 software; 
TNO, Biomedical Instruments, Amsterdam, the Netherlands). Intermittent arterial BP was 
measured to verify continuous BP measurements by brachial auscultation using an 
autosphygmomanometer (Dinamap, Germany). 
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Figure 3.1 Beat-by-beat arterial blood pressure measurement via finger 
photoplethysmography (Finapress). 
 
 
Mean skin temperature was measured using the weighted average of four regional 
temperatures measured from thermocouples (iButtons data logger; Maxim Integrated, San 
Jose, CA) fitted to a lateral calf, a lateral thigh, a tricep and the chest (Ramanathan, 1964). 
Core body temperature was measured via an ingestible telemetry pill (CorTemp, HQ Inc, 
Palmetto, FL) that was ingested approximately 6 hours prior to measurements. Mean body 
temperature was calculated using the weighted product of core and mean skin 
temperature (Stolwijk and Hardy, 1966).  
 
a)                                                                                                                                                               
 
 
 
b) 
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Figure 3.2 a) Thermocouple skin temperature sensor b) CorTempTM sensor c) CorTempTM 
data recorder. 
 
 
Cutaneous blood flow was measured using multi-fibre laser-Doppler flowmetry probes 
(Periflux System 5001; Perimed AB, Stockholm, Sweden) that were fixed with an adhesive 
heating ring. The laser-Doppler flow probes were positioned in an area that did not appear 
by visual inspection to be overly vascular. Calibration of the laser Doppler probes was 
performed using 2 generic points in accordance with manufacturers calibration guidelines 
using a zeroing disk and motility standard (Periflux System, Perimed AB). Sweat rate (SR) 
was continuously recorded via capacitance hygrometry with the ventilated capsule 
technique. Dry 100% nitrogen gas was supplied through acrylic capsules attached to the 
skin surface at a flow rate of 300 mL/min, with the humidity of the gas flowing out of the 
capsules measured by the capacitance hygrometer (Viasala HMP 155, Helsinki, Finland). 
Laser Doppler flowmetry probes and ventilated sweat capsules were secured to the chest 
and exposed forearm using tape.  
Cutaneous vascular conductance was calculated as the ratio of LDF to mean arterial 
pressure (MAP) and expressed as both CVC and a percentage of maximum CVC (%CVCmax). 
The sensitivity of the sweating responses was estimated using the slope of the linear 
relationship between sweat-rate-per-unit change in core temperature beyond the core 
c) 
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temperature threshold for sweating; any plateau was omitted from the slope calculation 
(Wingo et al, 2010). The same method was employed to estimate skin blood flow sensitivity 
but instead using the rate of CVC-per-unit change in core temperature (Wingo et al, 2010).  
 
 
 
(a) (b)
 
 
 
Figure 3.3 (a) Laser Doppler flowmetry probes fixed with an adhesive heating ring (b) 
capacitance hygrometry using ventilated capsule technique. 
 
 
Middle cerebral artery velocity (MCAv) was assessed bilaterally using transcranial Doppler 
(TCD) ultrasonography through the temporal window to insonate the middle cerebral 
artery (MCA), 1 cm distal to the MCA-anterior cerebral artery bifurcation. Vessel 
identification was achieved by probe direction, velocity, depth and waveforms. A Marc 600 
head frame (Spencer Technologies, Seattle, USA) secured 2-MHz Doppler probes (Spencer 
Technologies, Seattle WA, USA) and were adjusted until an optimal signal was found. 
Water-based gel was placed between the participant’s skin and the probe to reduce noise 
and artefact. Probe direction and TCD settings (depth, gain and power) were recorded once 
an optimal signal was identified to ensure comparable measurement post-intervention. 
Participants were asked to use a two-way valve-breathing (MLA1028, ADInstruments, 
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Colorado Springs, Colorado, USA) mouthpiece (MLA1026, ADInstruments) from which peak 
end tidal CO2 (PETCO2) was measured every 10 minutes for approximately 60 seconds using 
a calibrated gas analyser (ML206, ADInstruments). All data were sampled at 50 Hz with data 
acquisition hardware (PowerLab, ADInstruments, Oxford, UK) and displayed using LabChart 
data analysis software (ADInstruments, Colorado Springs, Colorado, USA).  
3.2.5 Cutaneous blood flow responses to local heating: 
Following whole body passive heating, local cutaneous heating was performed 
simultaneously at the chest and forearm laser-Doppler flowmetry sites to assess maximal 
cutaneous blood flow. The temperature of the adhesive heating ring was increased by 1°C 
every 5 seconds starting from 34°C and rising to 42°C. 
3.3 Data reduction 
Data from the passive heat stress test were extracted from LabChart. An average from ten 
minutes of thermoneutral rest was extracted as baseline. After which, 30 seconds averages 
throughout thermal heating were extracted. The onset of sweating and cutaneous 
vasodilation body/core temperature thresholds were identified via transient increases in 
SR and CVC. These thresholds were determined as the body/core temperature at the onset 
of chest and forearm SR and CVC in a blinded fashion by the same analyst. Sweating 
sensitivity was estimated using the slope of the linear relationship between SR per-unit 
change in mean body temperature beyond the mean body temperature threshold. Hot 
flushes during passive heating were omitted from the slope calculation to ensure accuracy 
of CVC and SR sensitivity calculations. This method was also employed for the estimation 
of skin blood flow sensitivity, using the rate of CVC per-unit-change in core temperature. 
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Data from the localised thermal heating test were extracted from LabChart using 30-second 
averages.  
Nineteen participants experienced a hot flush during laboratory testing. These hot flushes 
were objectively recorded in both normothermia (spontaneous) and during passive 
heating. A hot flush was defined as a transient and pronounced increase in sternal SR 
(>0.002 mg cm-2 min-1) (Freedman, 2001; Low et al, 2008; Bailey et al, 2016a). The end of a 
hot flush was recorded as the return of SR to baseline values prior to the hot flush. When 
hot flushes occurred with an absence of an increase in sweat rate, they were identified via 
a disruption in the ECG signal and a reduction in MCAv and BP. Following identification of 
a hot flush, each hot flush was divided into 8 equal segments, representing 12.5% of hot 
flush duration to account for variance in length of hot flushes. An average of every 30 
seconds from 2 minutes pre and 2 minutes post hot flush were extracted from LabChart.  
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4 Comparison of endocrine therapy 
mediated hot flushes vs 
postmenopausal hot flushes  
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4.1 Introduction 
Oestrogen receptor positive (ER+) breast cancer patients are prescribed endocrine therapy 
(e.g. SERMs and AI) after completion of active cancer treatment to reduce the recurrence 
of breast cancer. Nevertheless, 31-73% of patients prescribed endocrine therapy 
discontinued treatment before the end of the 5-year recommended use and 41-72% did 
not adhere to the prescribed frequency of use (Murphy et al, 2012). This is due to the side 
effect of hot flushes.  
A small number of studies have investigated the frequency and severity of hot flushes 
associated with breast cancer. Carpenter and colleagues employed ambulatory sternal skin 
conductance monitoring for 24 hours as well as subjective hot flush diaries and event 
markers to measure hot flushes in 19 postmenopausal breast cancer patients, three of 
which were taking tamoxifen, and five healthy premenopausal women. The study indicated 
that breast cancer patients subjectively under reported hot flush occurrence in comparison 
to objective measures as only 59% of hot flushes identified by skin conductance were 
recorded subjectively using either a diary entry or event marker (Carpenter et al, 1999).  In 
the same study, 15 ‘hot flushes’ were observed in premenopausal participants using skin 
conductance monitoring, but these increases in skin conductance were associated with 
increases in physical activity and/or performing exercise, suggesting that sternal skin 
conductance may not be able to differentiate between sweating from hot flushes and onset 
of sweating from increases in core temperature (Carpenter et al, 1999). In a subsequent 
study, Carpenter et al (2002) recruited 69 breast cancer patients, 50% taking tamoxifen, 
and 63 age-matched healthy pre-, peri- and postmenopausal females. A subjective hot flush 
questionnaire (Kronenberg, 1994) and a 48-hour hot flush diary were utilised to record 
frequency and severity of hot flushes. Overall hot flush frequency and severity were greater 
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in breast cancer patients over 48 hours by 4 hot flushes and 4 AU respectively compared to 
postmenopausal females. Carpenter and colleagues concluded that sternal skin 
conductance should not be utilised as a proxy measure of subjective hot flush intensity 
given that 47% of 569 subjective hot flushes were insufficient to meet objective criteria 
whilst 26% showed no change in skin conductance (Carpenter et al, 2005). A more reliable 
objective measure of hot flush frequency and severity is required to determine if hot 
flushes associated with breast cancer are indeed more frequent and severe compared to 
menopausal hot flushes.  
There are a greater number of studies, with more in-depth physiological measurement, 
that have investigated the frequency and severity of postmenopausal hot flushes (Low et 
al, 2008; Lucas et al, 2013). Indeed postmenopausal hot flushes are physiologically defined 
as a transient and pronounced increase in cutaneous vascular conductance (CVC) and skin 
blood flow (by ~80%), followed by a subsequent increase in sweat rate (500%) (Low et al, 
2008) and a reduction in MCAv (by ~5%) (Lucas et al, 2013). These physiological changes 
reflect the subjective descriptions from the hot flush questionnaires (e.g. Sloan et al, 2001). 
For example, the transient decrease in cerebral blood flow is likely responsible for the 
possible feelings of dizziness or nausea associated with a hot flush. Nevertheless, these 
objective physiological changes have not been described in endocrine therapy mediated 
hot flushes. Moreover, postmenopausal hot flushes have been linked with 
thermoregulatory dysfunction following the menopause and the severity of hot flushes 
have been associated with changes in vascular function (Bechlioulis et al, 2010). Again, this 
has not been explored in breast cancer patients receiving endocrine therapy and may 
provide important information for alleviating hot flushes. Therefore, the aim of the current 
study was to compare the subjective and physiological severity of hot flushes between 
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postmenopausal women and breast cancer patients undergoing endocrine therapy. It was 
hypothesised that the subjective and physiological frequency and severity of hot flushes 
would be increased in breast cancer patients undergoing endocrine therapy. A secondary 
aim was to compare thermoregulatory and vascular function in these 2 groups and it was 
hypothesised that thermoregulatory and vascular function in breast cancer patients would 
be impaired.  
4.2 Methods 
4.2.1 Participants 
Twenty-four participants (aged 53 ± 8 years; BMI 29.03 ± 5.27 kg/m2) were included in the 
current study. Participants were breast cancer patients taking aromatase inhibitors or 
tamoxifen (n=8), or age-matched naturally postmenopausal women measured from a 
previous study (n=16, Bailey et al, 2016b). Participants were recruited from Liverpool 
Women’s Hospital, Royal Liverpool and Broadgreen University Hospitals, local G.P. 
practices and via local advertisement. Postmenopausal females were 1-4 years since their 
last menstrual period and had not used hormone replacement therapy within the last 6 
months whilst breast cancer patients were > 3 months post active cancer treatment. All 
participants were experiencing > 4 hot flushes over a 24-hour period and postmenopausal 
females experienced a hot flush during the laboratory monitoring period. Both studies 
conformed to the Declaration of Helsinki and were approved by NHS research ethics 
committees. 
4.2.2 Research Design 
Participants attended the laboratory on two separate occasions. Participants fasted over-
night or at least 6 hours prior to the session, not having consumed alcohol for 24 hours and 
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caffeine for 12 hours or performed strenuous exercise for 24 hours before each visit. Visit 
one included anthropometric measurements, brachial artery endothelial function using 
FMD and a cardiorespiratory test (VO2peak). At conclusion of visit 1, a hot flush frequency 
and severity questionnaire was given to the participant to complete and return at visit 2. 
Visits were completed after 7 days and all measurements took place in a temperature-
controlled laboratory (24 ± 1 °C). Six hours prior to visit 2, participants consumed a 
thermometric pill to measure gut temperature as an index of core body temperature. At 
visit 2, temperature, local sweating, local skin and cerebral blood flow responses were 
measured during normothermia and throughout a thermal challenge and during any hot 
flushes that occurred during either period.  
4.2.3 Measurements 
Anthropometric measurements, brachial FMD, and VO2peak were undertaken as described 
in chapter 3 (sections 3.2.2 and 3.2.3). Subjective hot flush questionnaires (Sloan et al, 
2001) were completed over a 7-day period, between testing sessions (Chapter 3, sections 
3.2.1). MCAv, BP, HR, SV, cardiac output, PETCO2, LDF, CVC, SR, skin temperature and core 
temperature were measured throughout baseline and thermal test as described previously 
(Chapter 3, section 3.2.4). Following the thermal challenge, local cutaneous heating was 
performed at the chest and forearm using laser Doppler flowmetry, outlined in Chapter 3 
(section 3.2.5).  
4.2.4 Data Reduction 
Data were extracted before, during and after a hot flush identified as a transient and 
pronounced increase in sternal SR (>0.002 mg cm-2 min-1). During passive heating, data 
were extracted to establish thresholds for the onset of cutaneous vasodilation and 
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sweating and skin blood flow:core temperature, sweating:body temperature slopes. This is 
described in detail in Chapter 3 section 3.3. 
4.2.5 Statistical analysis 
All data was analysed using Statistical Package for Social Sciences (SPSS 23; Chicago, IL). 
Statistical significance was defined at p < 0.05 and exact p values are reported (p-values of 
“0.000” are reported as “< 0.001”). An independent t-test was employed for comparison of 
anthropometric measures, subjective hot flushes, resting MCAv, VO2peak, FMD, chest and 
forearm CVC and SR thresholds and CVC/SR: core temperature slopes of breast cancer 
patients undergoing endocrine therapy and postmenopausal women. A general linear 
model was used to analyse the relative change in chest and forearm CVC, chest and forearm 
SR, MCAv, CBVC, MAP and HR during a hot flush and to compare differences in breast 
cancer patients undergoing endocrine therapy and postmenopausal women. Data in the 
text are expressed as means and 95% confidence intervals, unless stated otherwise. 
4.3 Results 
4.3.1 Participants 
Age, height, weight, BMI, resting SBP, resting heart rate, resting MCAv and FMD were 
similar in breast cancer patients and postmenopausal women (P > 0.05, table 4.1).  DBP 
was 9 (-16, -2) mmHg lower and VO2peak was 3.48 (0.60, 6.37) ml.kg.min-1 higher in breast 
cancer patients undergoing endocrine therapy compared to postmenopausal women (P = 
0.02, Table 4.1). Breast cancer patients were taking tamoxifen (n=5), letrozole (n=2) or 
anastrozole (n=1).  
Table 4.1 Participant characteristics 
Characteristic Postmenopausal Breast cancer  P value 
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Age (years) 53 ± 4  53 ± 8 0.87 
Height (cm) 165.2 ± 5.7 162.9 ± 5.2 0.34 
Weight (kg) 78.0 ± 16.7 77.0 ± 16.1 0.89 
BMI (kg/m2) 29.0 ± 5.7 29.0 ± 5.7 0.99 
Resting SBP (mmHg) 129 ± 6 124 ± 17 0.45 
Resting DBP (mmHg) 77 ± 9 68 ± 7 0.02* 
Resting Heart Rate (beat.min-1) 69 ± 7 69 ± 13 0.49 
Resting MCAv (cm/s) 51.4 ± 5.3 58.9 ± 6.8 0.07 
VO2peak (ml.kg.min) 22.4 ± 2.3 25.9 ± 3.0 0.02* 
FMD (%) 5.1 ± 1.5 6.2 ± 2.7 0.29 
Subjective frequency of hot flushes 58 ± 20 49 ± 38 0.56 
Subjective severity of hot flushes (AU) 125 ± 49 81 ± 60 0.12 
Abbreviations: BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood 
pressure; MCAv, middle cerebral artery velocity; FMD, flow-mediated dilation; AU, 
arbitrary units. * Significant difference between groups. 
 
4.3.2 Hot flushes 
4.3.2.1 Subjective hot flushes:  
Breast cancer patients undergoing endocrine therapy experienced 9 (-45, 26) fewer hot 
flushes per week compared to postmenopausal women but this did not reach statistical 
significance (P = 0.56). Likewise, breast cancer patients rated their hot flushes as 44 (-102, 
13) AU lower compared to postmenopausal women (P = 0.12). 
Objective hot flushes: 
In total 32 objective hot flushes were recorded (11 endocrine mediated and 21 
menopausal).  
Hot flush duration: On average hot flushes were 139 (-205, -72) seconds shorter in breast 
cancer patients undergoing endocrine therapy compared to postmenopausal women (P < 
0.001).  
Hot flush haemodynamics: There was no main effect of time on MAP (P = 0.41). There was 
a group x time interaction in MAP (P < 0.001). MAP decreased by 4 mmHg in 
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postmenopausal women whilst in breast cancer patients increased by 4 mmHg throughout 
a hot flush (Table 4.2). MAP was on average 16 mmHg higher throughout the hot flush in 
breast cancer patients compared to postmenopausal women (main effect of group, P < 
0.001). On average, HR increased by 6 (4, 8) beat.min-1 during a hot flush (main effect of 
time, P = 0.04, Table 4.2). There was no group x time interaction in HR during hot flushes 
(P = 0.84). HR on average was 9 (1, 20) beat.min-1 lower in breast cancer patients 
undergoing endocrine therapy compared to postmenopausal women (main effect of group, 
P = 0.03).  
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Table 4.2 Haemodynamic responses during hot flushes in breast cancer patients and postmenopausal women undergoing passive heating. 
 Breast cancer Postmenopausal Group 
main 
effect 
Time 
main 
effect 
Group x 
time 
interacti
on 
Variable Baselin
e (2 
min) 
0% 50% 100% Post 
(+2 min) 
Baseline 
(2 min) 
0% 50% 100% Post 
(+2 min) 
MAP 
(mmHg) 
87 
(9) 
88  
(8) 
88  
(8) 
91 
(10) 
87 
(11) 
74 
(8) 
70 
(9) 
70 
(9) 
71 
(10) 
73 
(9) 
P < 0.001 P = 0.41 P < 
0.001 
HR 
(beat.min-1)  
70 
(10) 
69 
(11) 
72 
(11) 
72  
(13) 
72 
(9) 
80 
(13) 
84  
(13) 
87 
(13) 
82  
(13) 
81 
(18) 
P = 0.03 P = 0.04 P = 0.84 
CBVC (cm s-
1 mmHg-1)  
0.73 
(0.04) 
0.70 
(0.07) 
0.67 
(0.10) 
0.66 
(0.14) 
0.68 
(0.18) 
0.65 
(0.07) 
0.62 
(0.09) 
0.60 
(0.08) 
0.62 
(0.09) 
0.64 
(0.07) 
P = 0.02 P = 0.09 P = 0.21 
Data are presented as mean (SD). Hot flushes were statistically analysed over eight segments, but are represented over three time segments (0, 50, 100%) 
above. MAP, mean arterial pressure; HR, heart rate; CBVC, cerebrovascular conductance; SR, sweat rate.
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Cutaneous vascular conductance: There was a group x time interaction in the change in 
chest CVCmax from 2 minutes prior to a hot flush (P < 0.001) as the peak increase in chest 
CVCmax occurred later in breast cancer patients (at ~62.5% time point) compared to 
postmenopausal women (at ~12.5% time point). Overall, the change in chest CVCmax was 
5% (-1, 11) lower during a hot flush in breast cancer patients compared to postmenopausal 
women (main effect of group, P = 0.07, Figure 4.1). There was a group x time interaction 
for change in forearm CVCmax (P < 0.001). The peak increase in forearm CVCmax occurred 
later in breast cancer patients (at ~62.5%time point) compared to postmenopausal women 
(at ~12.5% time point). There was no main effect of group in change in forearm CVCmax (P 
= 0.14). The change in chest and forearm CVCmax increased by 12% (7, 16) and 16% (11, 20) 
during a hot flush, respectively (main effect of time, P < 0.001, Figure 4.1).  
 
 
 
 
 
Figure 4.1 Changes in chest and forearm cutaneous vascular conductance during hot 
flushes in breast cancer patients undergoing endocrine therapy (n=5 hot flushes) and 
postmenopausal women (n=21 hot flushes). Error bars are SD. BC, breast cancer patients. 
*Significant difference between groups (P < 0.05). 
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Sweat rate: There was a significant main effect of group in chest and forearm sweat rate (P 
< 0.05; Figure 4.2), as well as a significant main effect of time (P < 0.001). There was a group 
x time interaction in the change in chest (P = 0.004) and forearm (P < 0.001) sweat rate 
compared to 2 minutes prior to a hot flush. Overall, the change in chest sweat rate was 
0.05 (0.01, 0.09) mg.cm2.min-1 lower during a hot flush in breast cancer patients compared 
to postmenopausal women (Figure 4.2). Similarly, the change in forearm sweat rate was 
0.04 (0.01, 0.08) mg.cm2.min-1 lower during a hot flush in breast cancer patients compared 
to postmenopausal women.  
 
 
 
 
 
 
 
 
 
Figure 4.2 Changes in chest and forearm sweat rate during hot flushes in breast cancer 
patients undergoing endocrine therapy (n=5 hot flushes) and postmenopausal women 
(n=21 hot flushes). Error bars are SD. BC, breast cancer patients. *Significant difference between 
groups (P < 0.05). 
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Cerebral blood flow: There was a significant main effect of time as MCAv decreased by 0.06 
cm/s2 during a hot flush (P = 0.002). Yet, there was no main effect of group (P = 0.80, Figure 
4.3). There was a group x time interaction in MCAv (P = 0.01), the overall decrease in MCAv 
was 2.52 cm/s2 in breast cancer patients (-5.18, 1.4 cm/s2) whilst the decrease was 2.94 
cm/s2 in postmenopausal women (-5.11, -0.77 cm/s2). When expressed as CBVC, there was 
no significant group x time interaction (P = 0.21) or main effect of time (P = 0.09). Overall, 
CBVC was 0.07 cm/s2 (0.01, 0.14) mmHg higher during a hot flush by in breast cancer 
patients compared to postmenopausal women (main effect of group, P = 0.02, Table 4.2).  
 
Figure 4.3 Changes in MCAv during hot flushes in breast cancer patients undergoing 
endocrine therapy (n=5 hot flushes) and postmenopausal women (n=21 hot flushes). Error 
bars are SD. BC, breast cancer patients; MCAv, middle cerebral artery velocity. *Significant 
difference between groups (P < 0.05).  
 
 
4.3.3 Measurements during the heat stress challenge 
Thermoregulation: Basal core body temperature (P = 0.69) resting skin blood flow at the 
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was 3.51 CVCmax higher in breast cancer patients undergoing endocrine therapy compared 
to postmenopausal women (P = 0.05), whilst at the forearm, CVCmax was 3.60 CVCmax lower 
in breast cancer patients compared to postmenopausal women (P = 0.04). 
Cutaneous blood flow: The core temperature onset of chest (P = 0.42) and forearm (P = 
0.39) cutaneous vasodilation as well as the rate of change in chest (P = 0.52) cutaneous 
vasodilation during passive heating were similar in breast cancer patients and 
postmenopausal women. The rate of change in forearm cutaneous vasodilation during 
passive heating was higher in breast cancer patients compared to postmenopausal women 
(4.15, 1.76 CVC/°C; 95%CI: 0.12, 4.67; P = 0.04). 
Sweating: The core temperature onset of chest and forearm sweating were similar in breast 
cancer patients and postmenopausal women (P = 0.46; P = 0.56, respectively).   
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Table 4.3 Resting baseline data (mean ± SD) in breast cancer patients undergoing 
endocrine therapy (n = 7) and postmenopausal women (n = 16). 
Variable Breast 
cancer 
patients 
Postmenopausal 
women  
Mean 
difference 
Main effect 
of group 
Basal core body 
temperature (°C) 
36.77 ± 
0.64 
 
36.87 ± 0.24 0.10 0.69 
Basal chest CVC 
(AU/mmHg) 
0.46 ± 0.34 0.49 ± 0.23 0.04 0.81 
Basal forearm CVC 
(AU/mmHg) 
0.27 ± 0.20 0.25 ± 0.10 0.02 0.83 
Absolute chest 
vasodilatory threshold 
(°C) 
36.83 ± 
0.53 
37.02 ± 0.27 0.18 0.42 
Absolute forearm 
vasodilatory threshold 
(°C) 
36.89 ± 
0.50 
37.07 ± 0.21 0.18 0.39 
Rate of change in 
chest vasodilation 
(CVC.°C) 
3.61 ± 2.37 2.90 ± 2.21 0.71 0.52 
Rate of change in 
forearm vasodilation 
(CVC.°C) 
4.15 ± 2.18 1.76 ± 1.01 2.39 0.04 
Absolute chest 
sweating threshold 
(°C) 
36.92 ± 
0.60 
37.11 ± 0.24 0.18 0.46 
Absolute forearm 
sweating threshold 
(°C) 
36.97 ± 
0.58 
37.11 ± 0.24 0.14 0.56 
Data are presented as mean (SD). Tcore, core temperature; CVC, cutaneous vascular conductance. 
 
4.3.4 Cardiovascular Health 
Cerebral blood flow: Basal MCAv was 7.5 (-0.82, 15.75) cm/s greater in breast cancer 
patients undergoing endocrine therapy compared to postmenopausal women (P = 0.07; 
Table 4.1). When accounting for BP, CBVC was 0.12 (-0.25, 0 cm/s2) mmHg lower in breast 
cancer patients undergoing endocrine therapy versus postmenopausal women (P = 0.05).  
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Flow mediated dilation: Brachial artery FMD, time to peak diameter, peak response, shear 
rate area under curve and brachial artery diameter were similar in breast cancer patients 
undergoing endocrine therapy vs postmenopausal women (P > 0.05). Allometric scaling for 
baseline diameter did not alter results for the comparison of FMD between breast cancer 
patients undergoing endocrine therapy and postmenopausal women (P = 0.48).  
4.4 Discussion 
The primary aim of the current study was to compare the subjective and physiological 
severity of hot flushes between breast cancer patients undergoing endocrine therapy and 
postmenopausal women. Despite similar subjectively rated hot flush frequency and 
severity, breast cancer patients sweated less and had less pronounced skin and cerebral 
blood flow changes during a hot flush compared to postmenopausal women. Taken 
together, these data suggest that breast cancer patients undergoing endocrine therapy 
demonstrate less severe physiological hot flushes than postmenopausal women. 
The current study suggests that breast cancer patients undergoing endocrine therapy 
experience less severe hot flushes when objective physiological severity is measured; 
contrary to previous studies employing sternal skin conductance monitoring in breast 
cancer (Carpenter et al, 2002; Carpenter, Monahan and Azzouz, 2004). Typically, subjective 
questionnaires are utilised to assess hot flush frequency and severity with severity reported 
by individuals dependent on their symptom-based interpretations of sweating, cutaneous 
vasodilation and dizziness (Sloan et al, 2001). Whilst, the subjective hot flush severity was 
not statistically different between breast cancer patients and post-menopausal women in 
the current study, subjective rating was lower in breast cancer patients, which broadly 
supports the physiological observations during a hot flush. It is acknowledged that the low 
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number of participants in this study is a limitation and possible explanation for the lack of 
significance in the subjective data collected. Together with the short duration of hot flushes 
in breast cancer, the physiological and subjective data indicate endocrine mediated hot 
flushes are less severe than post-menopausal hot flushes. Yet, the sensitivity of breast 
cancer patients to hot flushes could potentially be increased compared to postmenopausal 
women as it took a smaller physiological change in breast cancer patients to generate a 
similar subjective rating as postmenopausal women.  
This is the first study to measure skin and cerebral blood flow responses during hot flushes 
alongside a measurement of sweating in breast cancer patients undergoing endocrine 
therapy. One noteworthy observation from the current study is that a small number of 
breast cancer patients did not demonstrate sweating during a hot flush. It is possible that 
breast cancer treatment e.g. chemotherapy, which can cause peripheral neuropathy, 
influences sweating responses during a hot flush or has a direct impact on the size and 
function of the sweat glands. Nevertheless, in the current study skin blood flow was also 
measured which is arguably a physiological response to the same signal (Johnson, Minson 
and Kellogg, 2014). Skin blood flow changes during a hot flush broadly show a similar 
temporal pattern to those observed in postmenopausal women (Low et al, 2008; Lucas et 
al, 2013; Bailey et al, 2016a; Bailey et al, 2016b), but the peak skin blood flow response 
during a hot flush occurred slightly later (i.e. in the middle of the flush rather than the 
beginning) in breast cancer patients undergoing endocrine therapy when compared to 
post-menopausal women. Typically, a hot flush is defined as an increase in skin blood flow 
prior to an increase in sweating (Low et al, 2008). It could be argued that the method 
utilised to identify the start of a hot flush contributed the temporal difference in the peak, 
as sweating above a certain threshold is the usual objective marker of a hot flush. In this 
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study, in the absence of sweating hot flushes were identified via other physiological 
variables including increases in skin blood flow and heart rate, decreases in MCAv and 
changes in MAP alongside any signal disruptions in ECG. Moreover, the overall magnitude 
of the change in skin blood flow was lower and the magnitude of the decline in cerebral 
blood flow was less in breast cancer patients undergoing endocrine therapy compared to 
postmenopausal women during a hot flush. Taken together, this data suggests that breast 
cancer patients undergoing endocrine therapy experience less skin reddening and dizziness 
during a hot flush and thus experience hot flushes of a reduced severity.  
Thermoregulatory and vascular function were similar but VO2peak and resting MCAv were 
higher in breast cancer patients compared to postmenopausal women. Whilst, the greater 
VO2peak levels in breast cancer patients is surprising given that VO2peak has been shown to 
be 24% lower in comparison to age- and sex-matched healthy controls (Jones et al, 2007); 
it is possible the breast cancer patients were indeed fitter or age/menopausal status was 
an influencing factor. The mean age of participants in both groups in the current study was 
similar, but there was a greater age range and both pre and post-menopausal women in 
the breast cancer group compared to postmenopausal women. Both fitness (Jackson et al, 
2009) and cerebral blood flow (Stoquart-ElSankari et al, 2007)  decline with age with large 
decrement after the menopause. It is possible that increased cardiorespiratory fitness 
levels found in breast cancer patients undergoing endocrine therapy in this study may be 
responsible for higher MCAv at rest compared to postmenopausal women as well as 
blunted physiological changes during hot flushes. However, it is not possible to separate 
the impact of the menopause on the current data set.  
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4.4.1 Conclusion 
This study found that despite comparable subjective hot flush frequency and severity data 
in breast cancer patients undergoing endocrine therapy and postmenopausal women; 
breast cancer patients demonstrated smaller changes in sweat rate, skin and cerebral blood 
flow during an objectively measured hot flush. Thus, indicating that the physiological 
severity of endocrine therapy mediated hot flushes are less severe than postmenopausal 
hot flushes.  
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5 Can exercise training reduce the 
frequency and severity of hot 
flushes in breast cancer patients 
undergoing endocrine therapy? 
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5.1 Introduction 
Endocrine therapy is prescribed to ER+ breast cancer patients after completion of ‘active’ 
cancer treatment. This type of breast cancer accounts for 80% of all cases. Endocrine 
therapy reduces the risk of breast cancer recurrence (Burstein et al, 2010). At least five 
years of endocrine therapy, with either tamoxifen or AIs, are recommended to ER+ breast 
cancer patients. Full compliance to tamoxifen reduces breast cancer mortality rate during 
the first 15-years post cancer treatment by at least one third (Early Breast Cancer Trialists' 
Collaborative, 2011). Likewise, AIs reduce breast cancer mortality by ~40% in the first 
decade of treatment (Early Breast Cancer Trialists' Collaborative, 2015). 
Despite the importance of endocrine therapy on morbidity and mortality (Burstein et al, 
2010), up to 90% of patients prescribed endocrine therapy discontinue or reduce their 
dosage due to the side effect of hot flushes (Murphy et al, 2012; Makubate et al, 2013). A 
hot flush is a sudden, intense sensation of heat causing skin reddening, flushing and profuse 
sweating (Low et al, 2008) corresponding to  elevations in skin blood flow, sweating and 
reductions in cerebral blood flow. Hot flushes have a direct negative impact on a breast 
cancer patient’s daily life and can cause anxiety, depression, sleep disturbances and chronic 
fatigue (Gupta et al, 2006). Targeting hot flushes in breast cancer patients undergoing 
endocrine therapy is essential to ensure women adhere to treatment guidelines as outlined 
by the NCRI Breast Cancer Symptom Management group and NICE guidelines for 
menopause (Julious, 2004; Morgan and Fenlon, 2013)  
The usual pharmacological treatment for hot flushes is hormone replacement therapy 
(HRT) but this is contraindicated in breast cancer. Therefore, there is a clear requirement 
to identify alternative treatments to target hot flushes. Alternative non-pharmacological 
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treatments such as cognitive behavioural therapy (CBT) and exercise have been proposed 
to alleviate hot flushes in breast cancer. Duijts and colleagues (2012) found that 12 weeks 
of combined CBT and exercise had a positive effect on hot flush frequency in breast cancer 
patients. Exercise alone, was found to decrease hot flush frequency, though not 
significantly. This lack of change could be due to no participant exercise supervision and 
the intervention may not have been of a sufficient exercise intensity. Exercise training in 
post-menopausal women, without breast cancer, led to a decrease in subjective and 
objective hot flushes (Bailey et al, 2016a; Bailey et al, 2016b). The changes in hot flushes 
coincided with improved thermoregulatory efficiency and improved vascular function. 
Taken together, the impact exercise training in breast cancer patients undergoing 
endocrine therapy warrants further investigation. 
The aim of the current study was to investigate if exercise training could reduce the 
subjective and objective frequency and severity of hot flushes in breast cancer patients 
undergoing endocrine therapy. In addition, a secondary aim was to assess changes in 
thermoregulatory and vascular function. It was hypothesised that 16-weeks of exercise 
training would reduce the subjective and physiological frequency and severity of hot 
flushes.   
5.2 Methods 
5.2.1 Participants 
Eight breast cancer patients at least 3 months post active treatment were recruited from 
the Royal Liverpool and Broadgreen University Hospital Trust (Table 5.1). Individuals with 
uncontrolled or severe hypertension or diabetes were excluded from the study.  
Participants were taking tamoxifen (n=5) or AI (n=3) and were experiencing >4 hot flushes 
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per day. The study was approved by the local NHS research ethics committee and adhered 
to the Declaration of Helsinki (2000).  
5.2.2 Research Design 
Participants arrived at the laboratory following a 6-hour fast not having consumed alcohol 
for 24 hours and caffeine for 12 hours or performed strenuous exercise for 24 hours before 
each visit. Participants completed a Physical Activity Readiness Questionnaire (PAR-Q) and 
an ECG was performed. Flow mediated dilation and VO2peak was assessed. Participants 
completed a subjective hot flush questionnaire for 7 days between visits. Six hours prior to 
visit 2, participants to consumed a thermometric pill to measure gut temperature as an 
index of core body temperature. Thermoregulatory responses were measured throughout 
a heat stress challenge. All measurements took place in a temperature-controlled 
laboratory (24 ± 1 °C).  
Supervised exercise training intervention: Participants completed a 16-week supervised 
exercise-training program. Exercise training was performed at a moderate intensity (~45-
70% HRmax), calculated through maximal HR reached during the participant’s 
cardiorespiratory fitness test. Exercise training involved 30 minutes of moderate intensity 
exercise 3 times per week for the first 4 weeks. Exercise training included treadmill 
walking/running, cycling, cross-training and rowing. Every four weeks, the intensity and 
duration of the exercise increased gradually so that by week 12, the participant was 
exercising for 60 minutes per session 5 times per week. At least one exercise training 
session per week was under supervision at the university gym. A moderate-intensity 
program was used in line with previous studies that have shown improvements in 
cardiorespiratory fitness (Hodges et al, 2010; Pugh et al, 2013; Sprung et al, 2013; Bailey et 
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al, 2016a; Bailey et al, 2016b). Participants wore a heart rate monitor (Polar Fitness, Polar 
Electro Oy, Finland) during all exercise sessions to track HR and ensure that they are 
reaching their target HR. To track compliance, participants were provided with a Bluetooth 
HR monitor (Polar H10, Polar Electro, Warwick, England) to record HR data from each 
training session (PolarBeat v: 2.5.0, Polar Electro, Warwick, England).   
Figure 5.1 Schematic of research design.  
 
5.2.3 Measurements 
During visit one, anthropometric measurements were obtained along with brachial FMD, 
carotid IMT and VO2peak, all described in chapter 3 (sections 3.2.2 and 3.2.3). A pre VO2peak 
screening 12-lead ECG (Riding et al, 2014) was completed to ensure participants were safe 
to perform exercise. A subjective hot flush questionnaire (Sloan et al, 2001) was completed 
during this 7-day period between visits. Participants wore a tube-lined suit (Med-Eng, 
Ottawa, Canada) which covered the entire body except for the head, feet and right 
forearm. During a thermal heating test, MCAv, BP, HR, SV, CO, PETCO2, LDF, CVC, SR, skin 
temperature and core temperature were measured as described previously (Chapter 3, 
section 3.2.4). Following whole body passive heating, local cutaneous heating was 
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performed at the chest and forearm using laser Doppler flowmetry, outlined in Chapter 3 
(section 3.2.5).  
5.2.4 Data Reduction 
Data were extracted from LabChart during normothermia, passive heating and during a hot 
flush.  In total 14 hot flushes were objectively measured in the laboratory. Onset thresholds 
for local sweating and cutaneous vasodilation and local sweating: mean body temperature 
and cutaneous vasodilation: core temperature slopes were established from this data (See 
general methods Chapter 3 section 3.3).  
5.2.5 Statistical analysis 
Analysis was conducted using the Statistical Package for Social Sciences (SPSS 23; Chicago, 
IL). Statistical significance was defined at p < 0.05 and exact p values are reported (p-values 
of “0.000” are reported as “< 0.001”). For comparison of all data from pre- to post-
intervention a paired sample t-test was employed. Thermoregulatory and haemodynamic 
responses before, during and after a hot flush were evaluated using a two-way general 
linear model with main effects of time (16 levels) and pre/post intervention (2 levels). Data 
in the text are expressed as means and 95% confidence intervals, unless stated otherwise. 
5.3 Results 
5.3.1 Participants 
Three of the women who were recruited dropped out of the study. Five participants were 
therefore measured pre and post intervention and adherence to exercise was 68%. Among 
the three women who did not continue, one dropped out due to having to discontinue 
endocrine therapy and two declined to return follow-up phone calls to ascertain the 
reasons for withdrawing.  
62 
 
Table 5.1 Participant characteristics (n=8) 
Characteristic Group 
Age (years) 53 ± 8 
Height (cm) 162.9 ± 5.2 
Weight (kg) 77.0 ± 16.1 
BMI (kg/m2) 29.0 ± 5.6 
Resting SBP (mmHg) 125 ± 18 
Resting DBP (mmHg) 69 ± 8 
Mean Arterial Pressure (mmHg) 89 ± 9 
Medication type (#): 
Tamoxifen 
Letrozole 
Anastrozole 
 
5 
2 
1 
Abbreviations: BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood 
pressure; MCAv, middle cerebral artery velocity; FMD, flow mediated dilation.  * Significant 
difference between groups. 
 
5.3.2 Hot flushes 
5.3.2.1 Subjective hot flushes:  
Subjective hot flush frequency was 40 (-21, 102) per week lower post exercise training 
compared to pre (P = 0.14, Figure 5.2). Similarly, subjective severity was 64 (-39, 166) AU 
lower post exercise training (P = 0.16, Figure 5.2).  
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Figure 5.2  Subjective hot flush frequency (# per week) and severity (AU) pre and post 
exercise training (n=4, due to one participant failing to return post exercise intervention 
questionnaires). Thick line indicates mean, solid lines are SD, empty circle indicates 
individual pre data whilst filled circles indicate individual post data. 
 
5.3.2.2 Objective hot flushes: 
In total 8 hot flushes were objectively measured in the laboratory (5 pre and 3 post).  
Hot flush duration: Hot flushes were 308 (-690, 74) seconds shorter pre training (103 ± 83 
seconds) compared to post training (411 ± 176 seconds; P = 0.08).  
Haemodynamics during hot flushes: HR increased by 7 beats min-1 during a hot flush (P = 
0.01; Table 3.2). There was no significant main effect of intervention (P = 0.60) or 
intervention x time interaction (P = 0.43). There was no main effects of intervention, time 
or intervention x time interaction in MAP (P > 0.05, Table 5.2).
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Table 5.2 Haemodynamic responses during hot flushes in breast cancer patients pre and post exercise training (n=5).  
 Pre Post Group 
main 
effect 
Time 
main 
effect 
Group x 
time 
interaction 
Variable Baseline 
(2 min) 
0% 50% 100% Post 
(+2 
min) 
Baseline 
(2 min) 
0% 50% 100% Post 
(+2 
min) 
MAP (mmHg) 90  
(12) 
85 (9) 83 (9) 88 (14) 89 (18) 95  
(17) 
91 (11) 88 (10) 95 (15) 92 (21) P = 
0.69 
P = 
0.20 
P = 1.00 
HR (beat.min-1)  66 
(15) 
69 (16) 70 (14) 71 (20) 75 (13) 77  
(16) 
79 (15) 83 (18) 84 (20) 79 (17) P = 
0.60 
P = 
0.01 
P = 0.43 
CBVC (cm s-1 
mmHg-1)  
0.74 
(0.06) 
0.71 
(0.07) 
0.69 
(0.10) 
0.70 
(0.11) 
0.62 
(0.30) 
0.53  
(0.02) 
0.55 
(0.10) 
0.56 
(0.09) 
0.54 
(0.11) 
0.56 
(0.06) 
P = 
0.11 
P = 
0.81 
P = 0.99 
Absolute chest SR 
(mg.cm2.min-1)  
0.19 
(0.07) 
0.19 
(0.07) 
0.22 
(0.08) 
0.20 
(0.07) 
0.19 
(0.07) 
0.26 
(0.19) 
0.27 
(0.21) 
0.41 
(0.19) 
0.34 
(0.19) 
0.30 
(0.21) 
P = 
0.26  
P < 
0.001  
P = 0.06 
Absolute forearm 
SR (mg.cm2.min-1)   
0.20 
(0.07) 
0.19 
(0.08) 
0.20 
(0.09) 
0.19 
(0.09) 
0.20 
(0.12) 
0.30 
(0.37) 
0.31 
(0.29) 
0.42 
(0.30) 
0.35 
(0.31) 
0.34 
(0.32) 
P = 
0.17 
P < 
0.001  
P < 0.001 
Data are presented as mean (SD). Hot flushes were statistically analysed over eight segments, but are represented over three time segments (0, 50, 100%) 
above. MAP, mean arterial pressure; HR, heart rate; CBVC, cerebrovascular conductance; SR, sweat rate. 
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Cutaneous vascular conductance: There was a significant main effect of time for chest skin 
blood flow (CVCmax) compared to pre hot flush baseline (P = 0.002). Similarly, there was a 
significant main effect of time in forearm CVCmax (P < 0.001). Yet, there was no main effect 
of intervention or intervention x time interaction in chest or forearm CVCmax during hot 
flushes (P > 0.05, Figure 5.3).  
 
 
 
 
 
 
 
Figure 5.3 Changes in chest and forearm cutaneous vascular conductance during hot 
flushes in breast cancer patients pre (n=5 hot flushes) and post (n=3 hot flushes) exercise 
training. Error bars are SD. 
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Sweat rate: There was a significant main effect of time in the change in chest and forearm 
SR compared to prior to a hot flush (P < 0.001). The change in chest and forearm SR 
increased by 0.91 ± 0.04 and 0.64 ± 0.01 mg.cm2.min-1 respectively during a hot flush. There 
was an intervention x time interaction in the change in forearm SR (P < 0.001), but not at 
the chest (P = 0.23). The change in forearm SR was greater post exercise training (0.09 
mg.cm2.min-1) compared to pre (0.02 mg.cm2.min-1). There was no main effect of 
intervention in the change in chest or forearm SR during hot flushes (P = 0.13, Figure 5.4). 
  
  
    
  
   
  
Figure 5.4 Changes in chest and forearm sweat rate during hot flushes in breast cancer 
patients pre (n=5 hot flushes) and post (n=3 hot flushes) exercise training. Error bars are SD.  
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Cerebral blood flow: There was no main effect for either intervention (P = 0.31) or time (P 
= 0.53) and no intervention x time interaction (P = 0.91) in MCAv during hot flushes (Figure 
5.5).  When expressed as CBVC, similar findings were evident (P > 0.05; Table 5.2).  
 
 
 
 
 
 
Figure 5.5 Changes in MCAv during hot flushes in breast cancer patients pre (n=5 hot 
flushes) and post (n=3 hot flushes) exercise training. MCAv, middle cerebral artery velocity. 
Error bars are SD. 
 
5.3.3 Measurements during the heat stress challenge 
Thermoregulation: Basal core body temperature (Table 5.3), resting skin blood flow (Table 
5.3) or CVCmax at the chest and forearm did not change pre to post exercise training (P > 
0.05). 
Cutaneous blood flow: There were negligible changes in the core temperature onset for 
chest and forearm cutaneous vasodilation and the rate of change in chest and forearm 
cutaneous vasodilation with exercise training (P > 0.05, Table 5.3).  
Sweating: There were negligible changes in mean body temperature onset for chest and 
forearm sweating and the rate of change in chest and forearm sweating with exercise 
training (P > 0.05, Table 5.3).  
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Table 5.3 Resting baseline data (mean ± SD) before and after exercise training (n=5). 
Variable Pre Post Change from 
pretraining 
Main effect of 
intervention 
Basal core body 
temperature (°C) 
36.68 ± 0.69 36.84 ± 0.63 0.16 P = 0.72 
Basal chest CVC 
(AU/mmHg) 
0.49 ± 0.43 0.37 ± 0.28 -0.12 P = 0.62 
Basal forearm CVC 
(AU/mmHg) 
0.30 ± 0.23 0.30 ± 0.19 0.00 P = 1.00 
Absolute chest 
vasodilatory threshold 
(°C) 
36.79 ± 0.56 36.99 ± 0.53 0.20 P = 0.61 
Absolute forearm 
vasodilatory threshold 
(°C) 
36.87 ± 0.52 37.01 ± 0.53 0.12 P = 0.72 
Rate of change in chest 
vasodilation (CVC.°C) 
2.20 ± 0.96 3.62 ± 2.44 1.42 P  = 0.45 
Rate of change in 
forearm vasodilation 
(CVC.°C) 
4.08 ± 1.04 2.96 ± 1.90 -1.12 P = 0.27 
Absolute chest sweating 
threshold (°C) 
36.92 ± 0.60 37.03 ± 0.39 0.18 P = 0.53 
Absolute forearm 
sweating threshold (°C) 
36.87 ± 0.63 37.00 ± 0.44 0.14 P = 0.74 
Rate of change in chest 
sweating (mg.min-
1.cm2.°C) 
0.88 ± 0.40 
 
0.36 ± 0.27 -0.52 P = 0.31 
Rate of change in 
forearm sweating 
(mg.min-1.cm2.°C) 
1.20 ± 0.23 0.51 ± 0.47 -0.69 P = 0.23 
Data are presented as mean (SD). Tcore, core temperature. 
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5.3.4 Measurements during local heating 
Maximal skin blood flow at the chest and forearm did not change post exercise training (P 
> 0.05). Likewise, maximal CVC during local heating at the chest and forearm were 
unchanged after exercise training (P > 0.05).  
5.3.5 Cardiovascular Health  
Cerebral blood flow: Resting MCAv did not change with exercise training (P = 0.27). This 
finding remained after accounting for BP (P = 0.31).   
Cardiorespiratory fitness and blood pressure: There were negligible differences in resting 
heart rate, systolic and diastolic BP (P > 0.05). VO2peak increased by 0.9 (-4.32, 2.52) 
ml.kg.min-1 after exercise training, yet this did not reach statistical significance (P = 0.46; 
Figure 5.6).  
Flow mediated dilation: There were no changes in conduit brachial artery endothelial 
function FMD%, shear rate area under curve, brachial artery diameter and FMD peak 
diameter with exercise training (P > 0.05). No change in FMD% remained after allometric 
scaling was performed (P = 0.57). There was a reduction of 29 (17.64, 39.60) seconds in 
time to peak dilation with exercise training (P = 0.002).  
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Figure 5.6 Cardiorespiratory fitness (VO2peak) before and after exercise training (n=4, due 
to technical issues with one pre exercise intervention test). Thick line indicates mean, solid 
lines are SD, empty circle indicates individual pre data whilst filled circles indicate individual 
post data.  
 
 
5.4 Discussion 
The aim of the current study was to compare subjective and physiological frequency and 
severity of hot flushes in breast cancer patients undergoing endocrine therapy following a 
16-week moderate-intensity exercise training intervention. The results of the study show 
that whilst exercise training reduced subjective hot flush frequency by 40 hot flushes per 
week and severity by 64 AU, this did not reach statistical significance. Moreover, the 
physiological responses during a hot flush including sweat rate, skin and cerebral blood 
flow were largely unchanged after exercise training. Taken together, these data suggest 
that exercise training in breast cancer patients undergoing endocrine therapy may not 
influence the frequency and severity of hot flushes. 
The results suggest that the exercise training intervention caused a reduction in subjective 
hot flush frequency and severity, although not statistically significant, that could be 
practically meaningful (~ 40 flushes per week), suggesting that exercise may have some 
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benefit. Nevertheless, a physiological marker of a hot flush, skin blood flow, did not show 
meaningful reductions following exercise training.  Yet, the increase in sweat rate after the 
exercise intervention may suggest an improved ability to dissipate heat and therefore 
reduce the severity of hot flushes. Likewise, there was some evidence of a positive cerebral 
blood flow change suggesting individuals experience less dizziness during hot flushes. 
These positive physiological changes in sweat rate and cerebral blood flow could potentially 
support the subjective data. Intriguingly, these findings in physiological measures in breast 
cancer patients undergoing endocrine therapy are in contrast to postmenopausal women 
(Bailey et al, 2016a), who demonstrated that not only did 16 weeks of moderate intensity 
exercise training mediate reductions in subjective hot flush severity but also mediated 
reductions in sweating, skin and cerebral blood flow during a hot flush. One potential 
explanation for the disparity in the objective markers and/or the findings from post-
menopausal women is that breast cancer patients do not have as severe hot flushes and 
some hot flushes do not have a sweating response, potentially due to peripheral 
neuropathy (study 1). The increased sweat rate during a hot flush post exercise training in 
breast cancer patients may suggest an improvement in peripheral neuropathy symptoms. 
It is acknowledged that the findings of the current study are based on a small number of 
women and further research with a larger sample size is required to support these 
preliminary observations.  
Another novel aspect of the current study was to investigate the thermoregulatory and 
vascular systems in response to exercise, given that these systems have been implicated in 
causal pathway for hot flushes (Bechlioulis et al, 2010; Freedman, 2014) and been shown 
to change with exercise training alongside alleviations in hot flushes in post-menopausal 
women (Bailey et al, 2016b). Nevertheless, there were negligible changes in sweat rate and 
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skin blood flow thresholds and sensitivities after 16 weeks of moderate intensity exercise 
training in breast cancer patients undergoing endocrine therapy. This could be linked to the 
lack of change in cardiorespiratory fitness in the current study; generally improvements in 
heat loss responses require an increase in cardiorespiratory fitness by 15-20% (Pandolf, 
Burse and Goldman, 1977). Breast cancer patients typically exhibit exercise intolerance as 
active cancer treatment can impact oxygen delivery, and utilisation (Jones et al, 2009). 
Nonetheless, results from study 1 demonstrate that VO2peak was similar in breast cancer 
patients compared to postmenopausal women and multiple studies have demonstrated 
increases in cardiorespiratory fitness in breast cancer patients after exercise training 
interventions (Nieman et al, 1995; Kolden et al, 2002; Courneya et al, 2003; Pinto et al, 
2005). Although participants attended exercise training sessions at the university gym most 
weeks, adherence to sessions on own accord was low which might explain the lack of 
change in fitness in the current study.  
Alternative explanations for exercise training not mediating improvements in skin blood 
flow during hot flushes, sweating and cutaneous vasodilatory thresholds or 
cardiorespiratory fitness could be related to time since beginning tamoxifen or AI. 
Mortimer et al (2008) found that hot flushes were more common in women who were 
closer to diagnosis and time since beginning tamoxifen treatment, whilst age and 
chemotherapy possessed no link. As no association between age and hot flush occurrence 
was reported in breast cancer patients, presumably menopausal status may also not be a 
key factor. On the other hand, the type of endocrine treatment may be associated with hot 
flushes. Breast cancer patients taking anastrozole have reported reduced hot flush 
occurrence compared to those taking tamoxifen (Howell et al, 2005). Thus, these differing 
mechanisms of action may influence hot flushes. 
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5.4.1 Conclusion 
In summary, this study found some preliminary evidence of a positive impact on subjective 
severity of hot flushes with exercise training. Nevertheless, there is little evidence that a 
16-week moderate intensity aerobic exercise training intervention reduces objective 
frequency and severity of hot flushes in breast cancer patients undergoing endocrine 
therapy. Whether these findings are explained by the endocrine therapy directly requires 
further investigation. 
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6 Research Synthesis 
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6.1 Aims and objectives 
Prior to the research work completed within this thesis, there was little insight into the 
physiology of hot flushes in breast cancer patients undergoing endocrine therapy and/or 
non-pharmacological alternatives to alleviate symptoms. The studies provide new data 
regarding differences between postmenopausal and endocrine mediated hot flushes as 
well as contribute to understanding of the effect of exercise training on endocrine 
mediated hot flushes.  
6.2 Major findings 
• Endocrine therapy mediated hot flushes are physiologically less severe than 
postmenopausal hot flushes 
• Exercise training had little impact of the frequency and severity of hot flushes in 
breast cancer patients undergoing endocrine therapy  
• Thermoregulatory and vascular control, alongside cardiorespiratory fitness, may be 
improved after exercise training in breast cancer patients 
6.3 Implications and future directions 
6.3.1 Breast cancer patients undergoing endocrine therapy demonstrate smaller changes 
in sweat rate, skin and cerebral blood flow, thus physiological severity, during a hot 
flush compared to postmenopausal women. 
The reduced physiological severity of hot flushes in breast cancer patients compared to 
postmenopausal women found in study 1 suggests that endocrine therapy may not prompt 
more severe hot flushes in these individuals. Although speculative, it could be possible that 
the breast cancer patients recruited in this thesis may possess a reduced sensitivity to a hot 
flush stimulus and therefore they may perceive hot flushes as less severe compared to 
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postmenopausal women. Further research recording subjective severity of physiologically 
measured hot flushes should be conducted. Education should be provided to both 
healthcare professionals and patients regarding the differences in endocrine mediated and 
menopausal hot flushes. How to deal with the differences needs to be explored in more 
detail.  
6.3.2 A number of hot flushes demonstrated no change in sweating  
Intriguingly, a number of endocrine therapy mediated hot flushes in this thesis 
demonstrated no change in sweat rate. Typically, a hot flush is defined as an increase in 
skin blood flow prior to an increase in sweating (Low et al, 2008). Figure 6.1 depicts an 
example of a hot flush in a breast cancer patient undergoing endocrine therapy with no 
change in sweat rate. This hot flush was identified via a transient increase in skin blood 
flow, decrease in cerebral blood flow, change in blood pressure and disruption to the ECG 
signal. The absence of sweating could suggest that peripheral mechanisms that initiate 
sweating are incapable of responding to stimuli in these individuals and therefore limit heat 
dissipation and/or sweat glands function differently in breast cancer patients in comparison 
to postmenopausal women. Participants could potentially report these hot flushes as more 
severe as they are unable to dissipate the heat. The subjective severity of hot flushes was 
not recorded during physiological measurements in this study so this hypothesis cannot be 
examined with the current data set. In accordance, data found in chapter 4 may suggest 
that hot flushes in breast cancer patients undergoing endocrine therapy may be mediated 
differently compared to postmenopausal women. This could suggest that different 
interventions may be required to demonstrate improvements in hot flushes in the differing 
population (discussed below).   
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6.3.3 Hot flushes in breast cancer patients undergoing endocrine therapy and 
postmenopausal women may be mechanistically different. 
Endocrine therapy per se could alter mechanisms mediating hot flushes, and thus be 
responsible for the physiological differences between endocrine mediated and 
menopausal hot flushes seen in chapter 4. Due to postmenopausal women experiencing 
more subjectively and physiologically severe hot flushes and possessing a reduced 
cardiorespiratory fitness in chapter 4, it could be postulated that this group would exhibit 
an increased amount of vascular and thermoregulatory dysfunction in comparison to 
breast cancer patients undergoing endocrine therapy. Yet, no differences in these variables 
were present. Endocrine therapy may therefore mediate hot flushes via alternative 
mechanisms, such as altering neural drive and autonomic function. Studies investigating 
these mechanisms require further attention including alternative interventions for 
example warm water immersion and/or sauna training may mediate thermoregulatory and 
Figure 6.1 LabChart output during a hot flush A) pink trace is ECG B) blue and dark green 
trace is cerebral blood flow C) gold trace is blood pressure D) light green and red trace are 
chest and forearm skin blood flow, respectively E) purple and blue trace are chest and 
forearm sweat rate, respectively. Black box specifies the hot flush.  
 
A) 
B) 
C) 
D) 
E) 
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vascular benefits via different mechanisms than exercise training (Green et al, 2010; Bailey 
et al, 2016c).  
 
6.3.4 Exercise training demonstrated little impact on physiological hot flush severity in 
breast cancer patients undergoing endocrine therapy 
This could be due to the lack of change in cardiorespiratory fitness. Postmenopausal 
women increased VO2peak by 4.5 ml.kg-1.min-1 after 16 weeks of aerobic exercise training 
(Bailey et al, 2016a; Bailey et al, 2016b) whilst breast cancer patients showed a 0.9 ml.kg-
1.min-1 increase in chapter 5. These results could suggest that an increased 
cardiorespiratory fitness is beneficial for thermoregulatory function and consequently 
reduces the severity of hot flushes. It is proposed that an improvement in VO2peak of 15-
20% is required to mediate beneficial thermoregulatory adaptations in premenopausal 
women (Pandolf, 1979; Ichinose et al, 2009). Adherence to the exercise training 
intervention in chapter 5 was poor in breast cancer patients (68%). Higher adherence to 
exercise training by participants could be encouraged by supervision of all exercise sessions 
and/or group exercise sessions. It is plausible to assume that greater changes in 
cardiorespiratory fitness could occur by higher adherence to exercise which in turn may 
induce thermoregulatory adaptations in breast cancer patients undergoing endocrine 
therapy. Nevertheless, chapter 5 demonstrated that the subjective hot flush frequency and 
severity was reduced post intervention. Hot flush frequency and severity was 77% and 83% 
respectively, lower after exercise training compared to pre-exercise. Although not 
statistically significant such a reduction could significantly improve quality of life, 
consequently be clinically relevant, and provide evidence for exercise training as a non-
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pharmacological intervention recommended for management of hot flushes in breast 
cancer patients undergoing endocrine therapy. Conversely, the subjective changes could 
be a result of a ‘placebo effect’ that is common for hot flush studies (Cancer Research UK, 
2015), whereby patients feel better after performing an intervention that they think will 
help. A larger randomised control trial is required to confirm these findings. 
6.4 Methodological considerations 
Strengths: Subjective hot flush severity was rated using a questionnaire and objective 
physiological measurements of hot flush severity were recorded that were independent of 
bias and perceptions. The physiological measures utilised in the current study may provide 
a more accurate representation of objective hot flushes in breast cancer patients. 
Nevertheless, it is recognised that physiologically measured hot flushes in a laboratory may 
not provide comparable results to hot flushes in everyday life.  
Limitations: During acute hot flush assessment using physiological measures in a 
laboratory, subjective severity of hot flushes was not reported. Additionally, in chapter 5, 
a small number of participants was likely insufficient to generalise findings to all breast 
cancer patients undergoing endocrine therapy. Chapter 5 also lacked a no-exercise control 
group. Thus, confirmation of these findings is required using a larger randomised controlled 
trial is warranted.  
6.5 Recommendations for future research 
Multiple potential areas of future research have emerged from the data reported in this 
thesis.  
1. A fully powered randomised control trial of exercise training compared to a no-
exercise control in breast cancer patients undergoing endocrine therapy.  
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2. An investigation into the impact of autonomic function and hot flush perception in 
breast cancer patients undergoing endocrine therapy compared to post-
menopausal women. 
3. A randomised control trial of water immersion/sauna training compared to 
conventional care in breast cancer patients undergoing endocrine therapy.  
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